As of 2024-12-13, the EV/EBITDA ratio of ExpreS2ion Biotech Holding AB (EXPRS2.ST) is 0.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EXPRS2.ST's latest enterprise value is -7.28 mil SEK. EXPRS2.ST's TTM EBITDA according to its financial statements is -75.95 mil SEK. Dividing these 2 quantities gives us the above EXPRS2.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 22.4x - 29.7x | 26.0x |
| Forward P/E multiples | 21.8x - 29.5x | 25.6x |
| Fair Price | (778.28) - (1,035.03) | (902.32) |
| Upside | -2783.7% - -3669.1% | -3211.4% |
| Date | EV/EBITDA |
| 2024-12-12 | 0.10 |
| 2024-12-11 | 0.08 |
| 2024-12-10 | 0.24 |
| 2024-12-09 | 0.26 |
| 2024-12-06 | 0.31 |
| 2024-12-05 | 0.29 |
| 2024-12-04 | 0.36 |
| 2024-12-03 | 0.38 |
| 2024-12-02 | 0.35 |
| 2024-11-29 | 0.32 |
| 2024-11-28 | 0.37 |
| 2024-11-27 | 0.38 |
| 2024-11-26 | 0.38 |
| 2024-11-25 | 0.37 |
| 2024-11-22 | 0.37 |
| 2024-11-21 | 0.35 |
| 2024-11-20 | 0.32 |
| 2024-11-19 | 0.32 |
| 2024-11-18 | 0.30 |
| 2024-11-15 | 0.30 |
| 2024-11-14 | 0.24 |
| 2024-11-13 | 0.19 |
| 2024-11-12 | 0.21 |
| 2024-11-11 | 0.20 |
| 2024-11-08 | 0.16 |
| 2024-11-07 | 0.15 |
| 2024-11-06 | 0.19 |
| 2024-11-05 | 0.15 |
| 2024-11-04 | 0.16 |
| 2024-11-01 | 0.07 |
| 2024-10-31 | 0.07 |
| 2024-10-30 | 0.03 |
| 2024-10-29 | -0.04 |
| 2024-10-28 | -0.03 |
| 2024-10-25 | -0.06 |
| 2024-10-24 | -0.06 |
| 2024-10-23 | -0.07 |
| 2024-10-22 | -0.06 |
| 2024-10-21 | -0.08 |
| 2024-10-18 | -0.09 |
| 2024-10-17 | -0.09 |
| 2024-10-16 | -0.14 |
| 2024-10-15 | -0.05 |
| 2024-10-14 | -0.07 |
| 2024-10-11 | -0.08 |
| 2024-10-10 | -0.06 |
| 2024-10-09 | -0.11 |
| 2024-10-08 | -0.14 |
| 2024-10-07 | -0.18 |
| 2024-10-04 | -0.11 |